A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs ASP 5094 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2018 Status changed from recruiting to active, no longer recruiting.